Are you offering Lutathera for multiple recurrent meningiomas?

Lutathera is currently only FDA-approved for treating somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). However, research is ongoing to explore its potential use for meningiomas, as many meningiomas express somatostatin receptors, which could make it a promising treatment option for patients who have exhausted surgical and EBRT options. A phase II study was conducted at the Mayo Clinic and presented at the last ASTRO Annual meeting this past fall in Washington, DC (Merrell et al., International Journal of Radiation Oncology 2024. In this trial of 20 patients, PFS-6 months of nearly 80% was observed. The authors concluded that "this rate greatly surpassed the benchmark from prior research, suggesting tha...